Study #2020-1042
Phase I/II Study of Autologous T Cells Engineered Using the Sleeping Beauty System to Express T-Cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects with Solid Tumors
MD Anderson Study Status
Not Accepting
Treatment Agent
Neoantigen specific TCR-T cell drug product, Aldesleukin (IL-2)
Description
A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Ovarian Cancer, Endometrial Cancer, Ovarian Carcinoma, Ovary Neoplasm, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Adenosquamous Cell Lung Cancer
Study phase:
Physician name:
Edmund Kopetz
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-844-580-2777
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.